An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301).

NCT01076010 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

277

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Renal Cell Carcinoma

Interventions

DRUG: Tivozanib
DRUG: Sorafenib

Sponsor

AVEO Pharmaceuticals, Inc.